Life Sciences News Roundup: Seagen Expands; questions and answers on veterinarians in biotechnology; seaweed capsules for intestinal bugs; After

Marc Cummings, CEO of Life Science Washington, at Life Science Innovation Northwest 2022. (Red Box Pictures Photo/Scott Eklund)

The Life Science Innovation Northwest 2022 meeting was live and in person this week in Seattle. Hundreds of researchers and entrepreneurs gathered at the city’s convention center, attending panels on everything from the science of cell therapy to the state of biotech funding in the current bear market.

The meeting began with a conversation between former Juno Therapeutics executives Hans Bishop and Steve Harr, who both co-founded Sana Biotechnology. The Seattle-based company went public last year in the largest-ever IPO for a preclinical biotech company. GeekWire covered the chat and then spoke with Bishop and Harr in an interview.

The meeting is hosted annually by the trade group Life Science Washington, which has a new CEO, Marc Cummings. I interviewed Cummings onstage at the reunion. He spoke about how to strengthen the industry and strengthen the workforce, as well as his organization’s priorities for the future.

Read on for these headlines and more of the week’s life sciences news from the Pacific Northwest.

– Juno Therapeutics examines Steve Harr and Hans Bishop on building startups, collaborating with tech, and more.

—LiWashington State Science Industry: New Business Group Leader on Sustaining Growth and Strengthening the Workforce

This female-led venture capital firm wants to fill ‘a huge gap’ in funding for women’s health startups

Biotech giant Seagen reveals plans for 270,000 square foot manufacturing facility near Seattle

— Univ. Washington researchers design and build custom machines from proteins

— Vancouver, Wash.-based biotech Absci opens new AI research lab At New York

Spirulina algae at Lumen Bioscience. (Picture Lumen)

More Pacific Northwest life sciences news below:

  • A single dose of the human papillomavirus vaccine works just as well as the standard three-dose schedule, opening the door to greater access around the world, according to a study led by UW global health professor Ruanne Barnabas.
  • The Aging Dogs Project, which describes how dogs age and tests whether the drug Rapamycin can extend lifespan, was featured in the Seattle Times. Funders of the University of Washington project include a consortium of technology entrepreneurs.
  • Lumen Bioscience of Seattle has completed a phase 1 study of its capsules for It’s hard infections, produced with green algae. Algae are engineered to produce three antibody-like proteins that neutralize a It’s hard toxin, as well as an enzyme that degrades the cell wall of the microbe. Data from the trial showed that the treatment got to the right place in the gut and that the therapeutic proteins were stable in the body, according to a press release. The company also recently published its preclinical data in a preprint and its approach in Natural biotechnology. The US Food and Drug Administration has given the green light to a phase 2 trial.

Comments are closed.